| Biogen Idec and Isis Pharmaceuticals Sign Second Rare Disease Option Agreement |
Abstract
|
|
Heather Cartwright |
|
| AstraZeneca Signs Two Deals to Advance its Virtual Neuroscience R&D Strategy |
Abstract
|
|
Heather Cartwright |
|
| Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement |
Abstract
|
|
Heather Cartwright |
|
| AstraZeneca Signs Second Licence Agreement with Rigel for Preclinical Asthma Drug |
Abstract
|
|
Heather Cartwright |
|
| Roche and Seaside Therapeutics Collaborate to Develop Disease-Modifying Therapies for Neurodevelopmental Disorders |
Abstract
|
|
Heather Cartwright |
|
| Ferring Licenses Late-Stage Constipation Drug from AstraZeneca Spinout Albireo |
Abstract
|
|
Heather Cartwright |
|
| Russia’s SatRx Licenses Exclusive Rights to Pfizer’s DPP-IV Inhibitor |
Abstract
|
|
Heather Cartwright |
|
| Evotec, Harvard and Janssen Form Three-Way Collaboration in Beta Cell Regeneration |
Abstract
|
|
Heather Cartwright |
|
| Merck & Co. Strengthens its HIV Pipeline with Two Licensing Deals |
Abstract
|
|
Heather Cartwright |
|
| Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline |
Abstract
|
|
Heather Cartwright |
|
| BMS Teams Up with AstraZeneca to Buy Amylin for US$7 B |
Abstract
|
|
Heather Cartwright |
|
| GlaxoSmithKline Secures Human Genome Sciences Takeover with Sweetened Offer |
Abstract
|
|
Heather Cartwright |
|
